These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 7601798)
21. Quality assurance and the drug development process: an FDA perspective. Leonard EM Qual Assur; 1994 Jun; 3(2):178-86. PubMed ID: 7804633 [No Abstract] [Full Text] [Related]
22. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316 [TBL] [Abstract][Full Text] [Related]
23. The web of clinical trial registration obligations: have foreign clinical trials been caught? Hathaway CR; Manthei JR; Haas JB; Meltzer ED Food Drug Law J; 2009; 64(2):261-75. PubMed ID: 19999283 [TBL] [Abstract][Full Text] [Related]
24. [New Japanese GCP--from the standpoint of a sponsor]. Ebi O Gan To Kagaku Ryoho; 1998 Apr; 25(5):650-62. PubMed ID: 9571962 [TBL] [Abstract][Full Text] [Related]
25. Regulation and review of DNA vaccine products. Smith HA Dev Biol (Basel); 2000; 104():57-62. PubMed ID: 11713825 [TBL] [Abstract][Full Text] [Related]
27. Regulatory Considerations for the Approval of Drugs Against Histomoniasis (Blackhead Disease) in Turkeys, Chickens, and Game Birds in the United States. Regmi PR; Shaw AL; Hungerford LL; Messenheimer JR; Zhou T; Pillai P; Omer A; Gilbert JM Avian Dis; 2016 Dec; 60(4):725-730. PubMed ID: 27902913 [TBL] [Abstract][Full Text] [Related]
28. Essential rules and requirements for global clinical trials in rare lung diseases: a sponsor's standpoint. Kuerner T Respir Investig; 2015 Jan; 53(1):2-6. PubMed ID: 25542597 [TBL] [Abstract][Full Text] [Related]
29. A study of warning letters issued to clinical investigators and institutional review boards by the United States Food and Drug Administration. Gogtay NJ; Doshi BM; Kannan S; Thatte U Indian J Med Ethics; 2011; 8(4):211-4. PubMed ID: 22106658 [TBL] [Abstract][Full Text] [Related]
30. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891 [TBL] [Abstract][Full Text] [Related]
31. Pediatric drug development in anesthesiology: an FDA perspective. Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624 [No Abstract] [Full Text] [Related]
32. Clinical investigation of new animal drugs by veterinary practitioners. Prater DA; Bertone JJ; Letonja T; Vaughn SD J Am Vet Med Assoc; 1996 Jan; 208(2):190-4. PubMed ID: 8567369 [No Abstract] [Full Text] [Related]
33. When to conduct a clinical trial. Boutrand JP Med Device Technol; 2004 Oct; 15(8):28-31. PubMed ID: 16225271 [TBL] [Abstract][Full Text] [Related]
34. Human subject protection; foreign clinical studies not conducted under an investigational new drug application. Final rule. Food and Drug Administration, HHS Fed Regist; 2008 Apr; 73(82):22800-16. PubMed ID: 18567164 [TBL] [Abstract][Full Text] [Related]
35. Probiotic foods and drugs: impact of US regulatory status on design of clinical trials. Hibberd PL; Davidson L Clin Infect Dis; 2008 Feb; 46 Suppl 2():S137-40; discussion S144-51. PubMed ID: 18181720 [TBL] [Abstract][Full Text] [Related]
36. The role of data audits in detecting scientific misconduct. Results of the FDA program. Shapiro MF; Charrow RP JAMA; 1989 May; 261(17):2505-11. PubMed ID: 2704109 [TBL] [Abstract][Full Text] [Related]
38. PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications. Karara AH; Edeki T; McLeod J; Tonelli AP; Wagner JA J Clin Pharmacol; 2010 Apr; 50(4):380-91. PubMed ID: 20097935 [TBL] [Abstract][Full Text] [Related]
39. Regulatory concerns for the chemistry, manufacturing, and controls of oligonucleotide therapeutics for use in clinical studies. Kambhampati RV; Chiu YY; Chen CW; Blumenstein JJ Antisense Res Dev; 1993; 3(4):405-10. PubMed ID: 8155982 [TBL] [Abstract][Full Text] [Related]
40. Academic investigator-initiated trials and the challenge of sponsor responsibility: the Cologne Sponsor Model. Georgias C; Grunow A; Olderog M; May A; Paulus U Clin Trials; 2012 Dec; 9(6):781-7. PubMed ID: 23104975 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]